XML 67 R12.htm IDEA: XBRL DOCUMENT v3.25.2
Lease
 6 Months Ended
Jun. 30, 2025
Lease  
Lease

4. Lease

 

On January 1, 2025, the Company assumed an office lease from Duraviva Pharma Inc. (“Duraviva”), a New York corporation under common control, through a lease assignment agreement. The lease term extends through August 31, 2026. The Company classified the lease as an operating lease. Upon adoption of ASC 842, the Company recognized right-of-use asset and corresponding lease liability for its operating lease.

 

 

The following summarizes information about the Company’s lease as of June 30, 2025 and December 31, 2024.

 Schedule of Lease

   2025   2024 
   For the Three Months Ended
June 30,		 
   2025   2024 
         
Amount recognized in the income statements          
           
Operating lease expense  $17,404   $- 

 

   2025   2024 
   For the Six Months Ended
June 30,		 
   2025   2024 
         
Amount recognized in the income statements          
           
Operating lease expense  $34,807   $- 

 

   As of
June 30, 2025		   As of
December 31, 2024		 
         
Amount recognized in the balance sheets          
           
Right-of-use assets  $75,837   $- 
Operating lease liabilities   76,452    - 
           
Lease commitment          
           
2025  $34,876   $- 
2026   46,955    - 
Total future minimum lease payments   81,831    - 
less imputed interest   (5,379)   - 
Present value of lease liabilities  $76,452   $- 
           
Supplement information          
           
Discount rate   11%   n.a. 
           
Remaining lease term   14 months    n.a.